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Abstract
Background: HIV-infected children in sub-Saharan Africa may be at a high risk of staying on a failing first-line
regimen and developing drug-resistance HIV variants due to lack of routine viral load monitoring. We investigated
whether cumulative viral load, measured as viremia copy-years (VCY) could predict morbidity in a setting where
viral load is not routinely monitored.
Methods: This was a single-center prospective observational longitudinal study of HIV-infected children initiating
antiretroviral therapy (ART) at the Pediatric HIV/AIDS Care program at Korle-Bu Teaching Hospital in Accra, Ghana.
The main outcome was morbidity measured as frequency of hospitalizations, opportunistic infections, and
outpatient sick visits. The main explanatory variable was viral load measured as VCY.
Results: The study included 140 children who initiated ART between September 2009 and May 2013 and had at least
2 viral load measurements. There were 184 hospitalizations, with pneumonia being the most common cause (22.8 %).
A total of 102 opportunistic infections was documented, with tuberculosis being the most common opportunistic
infection (68 %). A total of 823 outpatient sick visits was documented, with upper respiratory infections (14.2 %) being
the most common cause. Forty-four percent of our study participants had >4 log10 VCY. Children in this sub-cohort
had a higher frequency of sick visits compared with those with <4 log10 VCY (p = 0.03). Only 6.5 % of children with >4
log10 VCY had been identified as treatment failure using WHO clinical and immunological treatment failure criteria.
Conclusions: High level of cumulative viral load may translate to virological failure and subsequent increased all-cause
morbidity. Our finding of potential utility of VCY in pediatrics warrants further investigations. VCY may be a good
alternate to routine viral load measurement as its determination may be less frequent and could be personalized to
save cost.
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Background
The advent of antiretroviral therapy (ART) has reduced
HIV-associated morbidity and mortality in HIV-infected
individuals. The benefits of ART have been substantial in
sub-Saharan Africa, home to over 90 % of children living
with HIV/AIDS [1]. Unfortunately, with the unprece-
dented scale-up of ART in resource-limited countries and
the success of prevention of mother to child transmission
(PMTCT) of HIV, pediatric HIV ART coverage still lags
behind that of adults. At the end of December 2013, only
23 % of the 3.2 million children estimated to be living
with HIV were receiving ART [2]. The World Health
Organization (WHO) recently revised its recommendation
on when to start ART in children; ART should be initiated
among all children (<10 years of age) and adolescents
(10 to 19 years) living with HIV, regardless of WHO
clinical stage or CD4 cell count [3]. Based on this new
recommendation, ART coverage in children living with
HIV will increase sharply in the next couple of years.
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Increase in ART coverage will exacerbate the existing
challenges with laboratory monitoring of ART in
resource-limited countries. In resource-rich countries,
ART is monitored routinely with laboratory measures
such as blood chemistry, HIV viral load, and CD4 count
for early detection of medication side-effects and drug-
resistant viruses [4, 5]. The WHO recommendation for
ART monitoring has evolved over time from CD4 moni-
toring every six months and viral load testing only when
the capacity exists [6] to viral load being recommended
as the preferred monitoring approach to diagnose and
confirm treatment failure [3]. However, if viral load is
not routinely available, CD4 count and clinical monitor-
ing should be used to diagnose treatment failure [3].
This compromise is due to the fact that routine labora-
tory monitoring is not feasible in most resource-limited
countries due to cost, lack of technical expertise, and
lack of infrastructure [7]. Several studies from sub-
Saharan Africa have reiterated the need for universal
access to viral load monitoring of ART as clinical and
immunologic monitoring of treatment failure are not
sensitive enough [8–12]. We recently reported that the
rate of virological treatment failure after at least 24 weeks
on first-line regimen was 16.7 % in our pediatric HIV co-
hort in Ghana [13]. The virological treatment failure rate
in HIV-infected children receiving ART in sub-Saharan
ranges from 13 % to 44 % [14–16].
In many resource-limited settings, clinicians rely on
clinical and immunologic criteria to identify children fail-
ing first-line therapy. These criteria have low sensitivity
and positive predictive value of detecting virological fail-
ure [11, 17]. Thus without viral load monitoring of ART,
HIV-infected children in sub-Saharan Africa may be at in-
creased risk of staying on a failing first-line regimen and
developing drug-resistant HIV variants [18–20]. Viral load
is therefore an essential complementary test to CD4 cell
count [21] in monitoring treatment. The question, there-
fore, is not whether to do viral load testing in resource-
limited countries but what is the most cost-effective way
of monitoring viral load. Routine viral load monitoring
(every 3–4 months) in resource-rich countries over
20 years was found to have limited additional health bene-
fit considering the cost [22]. Taken together, there is a
need to explore different cost-effective viral load measures
such as less frequent, targeted, viral load measurements
(based on clinical and immune response to ART) and cu-
mulative viral load.
Given the grave consequences of virological treatment
failure both at the individual and population level, we
designed an exploratory prospective observational study
of HIV-infected children receiving care at Korle-Bu
Teaching Hospital in Accra, Ghana, to study biomarkers
for monitoring ART in children [13, 23]. The main
objectives of the current study were: (1) to evaluate
the association between cross-sectional viral load and
frequency of morbidity while on ART; and (2) to
explore whether cumulative viral load, measured as
viremia copy-years (VCY) [24], could predict morbi-
dity in a setting where viral load is not routinely
monitored.
Methods
Study population
This was a single-center prospective observational lon-
gitudinal study of HIV-infected children initiating ART
at the Pediatric HIV/AIDS Care program at Korle-Bu
Teaching Hospital in Accra, Ghana, from September
2009 to May 2013. Korle-Bu Teaching Hospital (KBTH)
is the largest tertiary hospital in Ghana. The Pediatric
HIV/AIDS Care program provides comprehensive HIV/
AIDS care to over 1100 children. All study participants
were on their first-line regimen. The first-line regimen
available at the clinic is non-nucleoside analog
(NNRTI)-based ART consisting of zidovudine (AZT),
lamivudine (3TC), plus either nevirapine (NVP) or efa-
virenz (EFV).
The rationale, organization, and recruitment of the
subjects for the cohort study have been previously de-
scribed [13]. In brief, we enrolled children aged 0 to
13 years whose biological parents or guardians agreed
to participate in a longitudinal study. Written consents
from parents or guardians and assents from children
were obtained before enrollment in the study. The par-
ticipants were seen and examined at the pediatric HIV
clinic every 4–6 months in accordance with local
standard-of-care. At enrollment and subsequent
follow-up visits, blood samples were collected for de-
termination of CD4 cell count/percentage, HIV viral
load, and complete blood count. The study was
reviewed and approved by the Ethics and Protocol
Review Committees of University of Ghana Medical
School and Yale University School of Medicine.
Study variables
Outcome variables
The main outcome measure was morbidity; measured as
frequency of hospitalizations, opportunistic infections,
and outpatient sick visits.
Explanatory variables
The main explanatory variable was viremia copy-years
(VCY). VCY was defined as the number of copies of HIV
RNA/ml/year [24]. Other variables included, gender, age,
caregiver type, parental HIV status, history of AIDS defin-
ing illness, duration of ART, and WHO clinical staging of
HIV infection.
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Other study measures
CD4 cell count and HIV viral load measurements
CD4 absolute cell count and percentage were quantified by
a dual-platform flow cytometry technology using a FACS-
Count system (Becton-Dickinson, Franklin Lakes, NJ, USA)
at the clinical laboratory at Korle-Bu Teaching Hospital
(KBTH) according to manufacturer’s instructions. HIV viral
load was measured using the COBAS® AmpliPrep and the
COBAS® TaqMan® 48 Analyzer (Roche Diagnostic Systems,
NJ, USA) for automated sample preparation and amplifica-
tion and detection, respectively. The limit of HIV-1 RNA
detection was 20 copies/mL. The laboratory partici-
pates in an external quality assurance testing program
by the South African Public Health Reference
Laboratory.
Definitions
WHO clinical treatment failure
WHO defines clinical failure as a new or recurrent clinical
event indicating advanced or severe immunodeficiency
(WHO clinical stage 3 and 4 clinical condition with excep-
tion of TB) after 6 months of effective ART [25].
WHO immunological treatment failure
WHO defines immunological failure as a CD4 count
of <200 cells/mm3 or CD4 < 10 % for children under 5;
and a CD4 count of <100 cells/ mm3 for children above
five years of age [25].
WHO virological treatment failure
WHO defines virological treatment failure as plasma
viral load above 1000 copies/ml based on two consecu-
tive viral load measurements after 3 months of ART,
with adherence support [25].
Statistical analysis
Descriptive measures were used to summarize the data.
Continuous variables were summarized using mean and
standard deviation (SD); categorical variables were sum-
marized using frequency and percent (%). Morbidity was
measured using frequency of hospitalizations, opportun-
istic infections, and outpatient encounters. VCY was cal-
culated as described above. A log10 transformation of
each viral load measurement was performed and the area
under the curve (AUC) was calculated. Participants were
stratified into 3 categories: those with <2log10 VCY (low
VCY), 2–4 log10 VCY (intermediate VCY) and >4log10
VCY (high VCY). Wilcoxon Rank Sum test and Fisher's
exact tests were used to compare continuous and categor-
ical variables, respectively, among the groups. Regression
analyses using logistic regression models were used to es-
timate the odds of having low, intermediate or high VCY.
Two-sided p-values are reported for all the statistical tests
used in the analysis. Analyses were performed using SAS
9.3 (Cary, NC).
Results
Characteristics of study participants
We included 140 children who initiated ART between
September 2009 and May 2013 with at least 2 viral load
measurements. There were no loss to follow up during
the study period. Table 1 summarizes the demographic
characteristics of the study group. Of the 140 children,
56 (40 %) were female and 84 (60 %) were male. The pri-
mary caregiver for the children in this study was pre-
dominantly the biological mother (62 %) but varied
considerably and included aunt (10 %), uncle (4 %),
father (9 %), grandmother (13 %), and stepmother (2 %).
Morbidity among study participants
Morbidity was measured as frequency of hospital admis-
sions, opportunistic infections, and outpatient sick visits.
There were a total of 184 hospital admissions, with
pneumonia – clinical and radiological diagnosis - being
the most common cause (22.8 %). A total of 102 events
of opportunistic infections was documented, with TB be-
ing the most common (68 %). A total of 823 outpatient
Table 1 Demographic characteristics of study participants
Characteristics Frequency
N = 140(%)
Age group (years)
≤5 18 (12.85)
6–12 95 (67.86)
13–17 27 (19.29)
Gender
Male 84 (60 %)
Female 56 (40 %)
HIV status of mother
Positive 93 (66.43)
Negative 4 (2.86)
Unknown 43 (30.71)
HIV status of father
Positive 34 (24.29)
Negative 17 (12.14)
Unknown 89 (63.57)
Caregiver
Aunt 14(10.00)
Father 12 (8.57)
Grandmother 18 (12.85)
Mother 87 (62.14)
Stepmother 3 (2.14)
Uncle 6 (4.28)
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sick visits was documented within the group, with upper
respiratory infections (14.2 %). Figure 1 illustrates the
five most common diagnoses for each of the morbidity
measures.
Association between viral load and morbidity
The mean follow up time was 4.3 years (SD ± 2.4). The
median number of viral load measurements was 2 with a
range of 2 to 8 measurements. We did not have uniform
number of viral load measurements among study partici-
pants due to periodic shortages of reagents and technical
difficulties with the viral load machine. We assessed
whether there was any correlation between the number
of viral load measurements and the outcome measures
of interest (i.e., frequency of hospitalizations, opportun-
istic infections, and outpatient sick visits. There was no
significant correlation between number of viral load
measurements and any of the outcome measures. We
then analyzed the temporal relationship between viral
load and the outcome measures (Fig. 2). As illustrated in
the time plots, the number of viral loads increased
steadily with time for each participant.
Viremia copy-year as predictor of morbidity
We investigated if any of the demographic characteristics
of the study participants could predict cumulative viral
load, measured as log10 VCY. Table 2 illustrates demo-
graphic characteristics of the study participants stratified
into three groups based on log10 VCY; participants with
<2 log10 VCY (N = 51), 2 to 4 log10 VCY (N = 27), and > 4
log10 VCY (N = 62). There was no statistically significant
association between any of the demographic characteris-
tics and VCY. Moreover, WHO clinical stage of a partici-
pant could not predict the level of VCY.
We investigated whether VCY was associated with
outcome measures of interest and other HIV disease
characteristics. Table 3 illustrates the bivariate analyses
of disease characteristics of the study group stratified by
VCY. There was no statistically significant difference in
the number of years of follow-up among the 3 groups.
We did not find any significant association between
VCY and the number of opportunistic infections, or
hospital admissions. However, the group with >4 log10
VCY had statistically significant outpatient sick visits
compared with the other 2 groups (p = 0.03). Of note,
only 6.5 % (4 of 58) in the group with >4 log10 VCY had
been identified as treatment failure using WHO clinical
and immunological definitions of treatment failure.
There was no significant association between VCY and
number of years of follow up.
Discussion
Forty-four percent of our study participants (62 of 140)
had >4 log10 VCY. Interestingly, only 6.5 % of the
Fig. 1 Top-five causes of morbidity among our pediatric cohort.
a. Five most common diagnoses for outpatient sick visits. b. Five
most common opportunistic infections. c. Five most common
diagnoses for hospitalization
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participants with >4 log10 VCY were identified as meet-
ing the WHO criteria for clinical and immunological
treatment failures [25]. Moreover, participants with >4
log10 VCY had statistically significant increased out-
patient encounters compared with participants with <4
log10 VCY. We found poor sensitivity of clinical and
immunologic assessments in determining treatment
failure, consistent with other pediatric studies from sub-
Saharan Africa [8, 10, 11]. Taken together, our study val-
idates the need for viral load monitoring as part of
pediatric HIV care in resource-limited setting. Although
implementation of viral load monitoring will continue to
Fig. 2 Time plots of viral load and morbidity among our pediatric cohort. Each follow up visit is represented with a dash; X is follow up visit
where viral load was measured; dark rectangle represent outcome measure. a. Outpatient sick visits. b. Opportunistic infections. c. Hospitalization.
d. Composite outcome; sum of hospitalization, opportunistic infections and outpatient sick visits
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be constrained by budgetary and technical constraints in
a resource-limited setting, there is an urgent need for in-
novative and cost-effective algorithms to include viral
load monitoring for accurate and timely diagnosis of
treatment failure.
We did not find statistically significant associations be-
tween cumulative viremia and frequency of opportunis-
tic infections or hospitalizations during the study period.
However, persistent viremia may have deleterious conse-
quences with time. Interestingly, there are reports of an
association between transient viremia and virological
failure [26–28], depletion of CD4+ T-cells [29], and
emergence of HIV drug resistant viruses [30, 31]. The
hallmark of HIV infection is progressive depletion of CD4
T-cells leading to development of opportunistic infections
(OIs), AIDS, and death [32]. HIV viral load has been found
in several studies to be the main determinant of HIV dis-
ease progression [4, 33–35]. In a resource-limited setting,
the two immediate deleterious effects of persistent viremia
will be virological treatment failure and evolution of HIV
drug resistant variants. Since the reported sensitivity of
clinical/immunological monitoring in detecting treatment
failure is low, 29 %-33 % [36], many of these children will
continue to be on failing first-line regimens. Several stud-
ies have shown that delayed detection of virological failure
to first-line therapy often leads to development of drug re-
sistance, jeopardizing potential second-line treatments
[11, 37, 38].
There is a paucity of data on the use of VCY, a measure
of cumulative viremia, in monitoring ART in HIV-
infected children. Two earlier pediatric studies found no
association between cumulative viremia and virological
failure or drug resistance [39, 40]. However, two recent
studies reported findings consistent with our findings [41,
42]. Thorvaldsson et al. reported that for every 10-fold in-
crease in viremia copy-years, there was about 8.5-fold in-
crease in the risk of morbidity and mortality among a
cohort of perinatally HIV-infected children in New Haven,
CT, USA [41]. Rossouw et al. found that cumulative
viremia in children on protease inhibitor (PI)-based ART
was associated with development of PI resistant mutations
[42]. In HIV-infected adults, there are several reports of
significant association between VCY and morbidity and
mortality [10–14]. Cole et al. reported that each log10
Table 2 Baseline demographic characteristics of study participants stratified by Log10 copy-years/mL
Characteristics Less than 2 AUVLC
(Log10 copy-years/mL) (N = 51)
Between 2 and 4 AUVLC
(Log10 copy-years/mL) (N = 27)
Greater than 4 AUVLC
(Log10 copy-years/mL) (N = 62)
P value*
Age 4.6 (2.9, 51)a 4.1 (3.0, 27) 5.4 (3.1, 62) 0.1327
HIV status of father 0.4012
Yes 14 (73.7)b 1 (33.3) 19 (65.5)
No 5 (26.3) 2 (66.7) 10 (34.5)
HIV status of mother 0.5237
Yes 36 (97.3) 18 (100.0) 39 (92.9)
No 1 (2.7) 0 (0.0) 3 (7.1)
Gender 0.2792
Female 16 (31.4) 13 (48.1) 27 (43.5)
Male 35 (68.6) 14 (51.9) 35 (56.5)
Care Giver 0.4816
Aunt 4 (7.8) 2 (7.4) 8 (12.9)
Father 3 (5.9) 5 (18.5) 4 (6.5)
Grandmother 4 (7.8) 3 (11.1) 11 (17.7)
Mother 36 (70.6) 17 (63.0) 34 (54.8)
Stepmother 1 (2.0) 0 (0.0) 2 (3.2)
Uncle 3 (5.9) 0 (0.0) 3 (4.8)
WHO clinical Stage 0.9904
Stage I 6 (21.4) 2 (13.3) 6 (14.6)
Stage II 6 (21.4) 4 (26.7) 9 (22.0)
Stage III 10 (35.7) 6 (40.0) 17 (41.5)
Stage IV 6 (21.4) 3 (20.0) 9 (22.0)
*The p value was generated using Wilcoxon Rank Sum test and Fisher’s Exact test for continuous and categorical variables, respectively
aMean (STD, N) for continuous variables
bNumber, N(%)for categorical variables
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increase in VCY was associated with 1.70-fold increased
hazard of AIDS or death among HIV seroconvertors, inde-
pendent of duration of infection, age, race, CD4 cell count,
viral load set-point, peak viral load, or most recent vial
load [24]. The authors concluded that VCY is a better
prognostic indicator of HIV disease progression than trad-
itional single measures of viremia. Reports from other co-
horts have reiterated that VCY is a better predictor of
HIV all-cause mortality [43–45]. Taken together, viral load
monitoring irrespective of the approach taken is critical
for any HIV program. Therefore, the WHO in 2013
recommended viral load monitoring as the preferred ap-
proach in evaluating treatment failure [25].
The rationale for the new recommendation is to: (1)
provide an early and more accurate detection of treatment
failure and guide appropriate switch from first to second-
line drugs to reduce the accumulation of drug-resistance
mutations; and (2) help to differentiate between treatment
failure and non-adherence [46]. However, there are several
challenges involved in implementing these recommenda-
tions in resource-limited settings including costs of the
test, costs of second-line drug regimens, accessibility to
centers who offer the tests, and lack of laboratory infra-
structure [47, 48]. For example, during our study period,
we faced several occasions where there were no reagents
to run viral load, breakdown of the equipment, technical
problems, or power outages. These obstacles led to re-
scheduling patients for blood draws for viral load, and
most patients subsequently failed to attend the resched-
uled appointments due to lack of time or transportation.
Despite the myriad of constraints in performing routine
viral load monitoring in resource-limited settings, there is
a need for countries to invest in innovative and cost-
effective monitoring of HIV treatment. VCY may be a
good alternate to routine viral load measurement or part
of clinical/immunological criteria to improve sensitivity of
detecting treatment failure. It also appears to be a good
surrogate for persistent viremia, a determinant of HIV dis-
ease progression and non-AIDS-associated clinical events.
To adopt VCY as part of treatment monitoring, there will
be a need for studies to establish the “set-point” for VCY
and how often to determine VCY. It may be possible to
have multiple viral loads during the first year on therapy
to determine one’s VCY “set-point” and thereafter the
Table 3 HIV disease characteristics of study participants stratified by Log10 copy-years/mL
Characteristics Less than 2 AUVLC
(Log10 copy-years/mL) (N = 51)
Between 2 and 4 AUVLC
(Log10 copy-years/mL) (N = 27)
Greater than 4 AUVLC
(Log10 copy-years/mL) (N = 62)
P value*
Overall Follow up time (in years) 4.6 (3.2, 51)a 4.6 (2.8, 27) 4.3 (1.7, 62) 0.96
AUVLCb (copy-years/mL) 52839.09 (200451.75, 51) 334006.10 (963952.93, 27) 142793.89 (360264.57, 62)
Number of opportunistic infections 0.7 (0.8, 51) 0.7 (0.6, 27) 0.8 (0.8, 62) 0.78
Number of outpatient sick visits 1.8 (2.1, 51) 2.3 (1.9, 27) 2.6 (2.3, 62) 0.08
Number of hospitalizations 0.9 (0.8, 51) 0.9 (1.1, 27) 0.8 (1.1, 62) 0.44
Number of composite events 3.6 (2.8, 140) 3.2 (2.5, 51) 3.7 (2.3, 27) 0.33
Clinical/Immunological Treatment Failure 0.49
Yes 2 (4.2)c 0 (0.0) 4 (6.5)
No 46 (95.8) 26 (100.0) 58 (93.5)
Opportunistic infections 0.90
Yes 27 (52.9) 16 (59.3) 35 (56.5)
No 24 (47.1) 11 (40.7) 27 (43.5)
Outpatient sick visits 0.03
Yes 33 (64.7) 22 (81.5) 53 (85.5)
No 18 (35.3) 5 (18.5) 9 (14.5)
Hospitalization 0.13
Yes 34 (66.7) 14 (51.9) 30 (48.4)
No 17 (33.3) 13 (48.1) 32 (51.6)
Composite Eventsd 0.39
Yes 47 (92.2) 27 (100.0) 57 (91.9)
No 4 (7.8) 0 (0.0) 5 (8.1)
*The p value was generated using Wilcoxon Rank Sum test and Fisher’s Exact test for continuous and categorical variables, respectively
aMean (STD, N) for continuous variables
bAUVLC, area under viral load curve
cNumber, N(%)for categorical variables
dComposite events, sum of hospitalization, opportunistic infections and outpatient sick visits
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frequency could be personalized. Less frequent viral load
determination might be cost-saving in the long-term.
Even though our study is one of the first studies to inves-
tigate the utility of VCY in monitoring ART in HIV-
infected children, it has several limitations. First, this is a
single tertiary center study and, therefore, one has to be
cautious in generalization of our findings to all HIV care
centers in resource-limited settings. Also, the small sample
size limits the generalization of our findings. Moreover, viral
load was not ascertained at regular interval so we could not
adjust for transient viremia in the analysis. Due to periodic
shortage of reagents or technical problems, viral load mea-
surements were not available at each clinic visit or on
scheduled dates. Since the viral loads were not uniformly
missing at random among study participants we could not
use any statistical test to account for data missing at ran-
dom. Furthermore, data on adherence was not uniformly
available in participants’ medical records so we could not
model adherence in our analyses. Most of these limitations
reflect the realities of carrying out observational cohort
studies in a resource-limited setting. Our findings suggest
potential utility of VCY in pediatrics, and this warrants fur-
ther investigations in resource-limited settings.
Conclusions
In conclusion, an unexpectedly high proportion of our
study participants had increased cumulative viral load.
This may translate to virological failure on their first-line
regimen and subsequent increased all-cause morbidity.
Our finding supports the current WHO recommenda-
tion of viral load monitoring as the preferred method for
monitoring ART in resource-limited countries. HIV
treatment programs in resource-limited countries should
come up with innovative and cost-effective algorithms
including viral load measurement for accurate and
timely diagnosis of treatment failure. VCY may be a
good alternate to routine viral load measurement as its
determination may be less frequent and could be per-
sonalized and therefore a potential cost-saving approach.
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